跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IL-17A targeting
首页
药物
IL-17A targeting
IL-17A targeting
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR TNFA AND IL-17A, ANTIBODIES TARGETING IL-17A, AND METHODS OF USE THEREOF
US 2022127350 A1
申请人: NUMAB THERAPEUTICS AG
优先权: 2019
CN
EP
US
WO
8 件公开
BISPECIFIC FUSION PROTEIN TARGETING TNF-? AND IL-17A, AND USE THEREOF
EP 4635988 A1
申请人: JIANGSU KANION PHARMACEUTICAL CO LTD
优先权: 2022
CN
EP
US
WO
4 件公开
METHOD FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
EP 4653009 A1
申请人: SHANGHAI HUAOTA BIOPHARMACEUTICAL CO LTD
优先权: 2023
CN
EP
WO
3 件公开
BISPECIFIC ANTIBODY TARGETING IL-17A AND IL-36R AND APPLICATION THEREOF
EP 4289863 A9
申请人: SHANGHAI HUAOTA BIOPHARMACEUTICAL CO LTD
优先权: 2020
CN
EP
2 件公开
METHODS AND COMPOSITIONS FOR MODULATING IL-17F/IL-17A BIOLOGICAL ACTIVITY
US 2008241130 A1
申请人: WRIGHT JILL F
优先权: 2008
US
TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS USING ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A)
CN 112203685 A
申请人: REMD BIOTHERAPEUTICS INC
优先权: 2018
CN
ANTIBODIES TARGETING IL-17A AND METHODS OF USE THEREOF
EP 3689907 A1
申请人: NUMAB THERAPEUTICS AG
优先权: 2019
EP
Therapeutic use of targeting IL-17A as resistance to leukemia
CN 116549631 A
申请人: INST MED BIOTECHNOLOGY CAMS
优先权: 2022
CN
Bivalent IL-17 therapeutic vaccine as well as preparation method and application thereof
CN 118681005 A
申请人: SHANGHAI HUIDUN YINTAI BIOTECHNOLOGY CO LTD
优先权: 2023
CN
Pharmaceutical compositions comprising antibodies targeting IL-17A
CN 118078988 A
申请人: CHIA TAI TIANQING PHARMACEUTICAL GROUP NANJING SHUNXIN PHARMACEUTICAL CO LTD
优先权: 2024
CN
第 1 / 2 页
上一页
下一页
药物
反馈